NCT01397994

Brief Summary

This study is to determine the anti-anginal and anti-ischemic effect of k-channel opener, nicorandil in patients of chronic stable angina.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Sep 2011

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 18, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 20, 2011

Completed
1 month until next milestone

Study Start

First participant enrolled

September 1, 2011

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2012

Completed
Last Updated

December 8, 2011

Status Verified

December 1, 2011

Enrollment Period

4 months

First QC Date

July 18, 2011

Last Update Submit

December 7, 2011

Conditions

Keywords

Nicorandil therapy in patients of chronic stable angina

Outcome Measures

Primary Outcomes (1)

  • SPECT Tc99m- Tetrofosmin (MYOVIEW)

    Changes in perfusion will be evaluated in each arm at week 4 and comparison between the two study arms will be made to document the anti ischemic effects of nicorandilusing Ex- SPECT MPI. * Improvement in SDS after 4 weeks of treatment (Summed Stress Score SSS, Summed Rest Score SRS, Summed Difference Score SDS) * Difference in number of reversible, partially reversible defects. * Improvement in the extent and severity of ischemic lesions.

    4 weeks

Secondary Outcomes (1)

  • Exercise ECG Testing - Bruce protocol

    4weeks

Study Arms (2)

Nicorandil test arm

ACTIVE COMPARATOR

Nicorandil is given with atenolol therapy.

Drug: Nicorandil

Atenolol control arm

ACTIVE COMPARATOR

Atenolol 50 mg OD is given.

Drug: Atenolol

Interventions

Patients would be advised 10mg bd nicorandil for the first seven days. Drug will be titrated to 20 mg bd after one week, atenolol 50 mg will be given along with nicorandil from day 1

Also known as: Nicorandil/ Nicoril
Nicorandil test arm

Patients in the control arm would be advised atenolol 50 mg od

Also known as: Atenolol/Atenorm
Atenolol control arm

Eligibility Criteria

Age25 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients of chronic stable angina with abnormal Exercise Myocardial Perfusion Spect Scan with reversible and partially reversible ischemic changes.
  • Male and female
  • Age 25 to 65 years
  • Patient must understand and be willing, able and likely to comply with all study procedures and restrictions and comprehends the diary cards.
  • Patient must be able to give voluntary written informed consent.

You may not qualify if:

  • Hypertension of \> 170/100 mm of Hg
  • Valvular heart disease and cardiomyopathy
  • Myocardial infarction in \< 6 months
  • Unstable angina
  • Congestive cardiac failure
  • Severe anemia (Hb 7G/dl)
  • Cardiac arrhythmias or II or III degree AV block
  • Significant liver or renal dysfunction
  • IDDM (Type-1 diabetes mellitus)
  • Systolic blood pressure \< 100 mm Hg
  • Pregnant and nursing women
  • Known hypersensitivity to nicorandil
  • On calcium channel blockers
  • Patients not eligible for Tc 99m SPECT
  • Patients in whom beta blockers are contraindicated
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institute of Cardiovascular Diseases

Karachi, Sindh, 75850, Pakistan

RECRUITING

MeSH Terms

Conditions

Angina, Stable

Interventions

NicorandilAtenolol

Condition Hierarchy (Ancestors)

Angina PectorisMyocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesChest PainPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

NitratesOrganic ChemicalsNiacinamideNicotinic AcidsAcids, HeterocyclicHeterocyclic CompoundsPyridinesHeterocyclic Compounds, 1-RingPhenoxypropanolaminesPropanolaminesAmino AlcoholsAlcoholsPropanolsAmines

Study Officials

  • Tariq Ashraf, MBBS,FCPS,FACC,FSCAI

    National Institute of Cardiovascular Diseases

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Tariq Ashraf, MBBS,FCPS,FACC,FSCAI

CONTACT

Hamid Tirmizey, MBBS,BSC,DIP.CARD.

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor Of cardiology, National Institute of Cardiovascular Diseases

Study Record Dates

First Submitted

July 18, 2011

First Posted

July 20, 2011

Study Start

September 1, 2011

Primary Completion

January 1, 2012

Study Completion

January 1, 2012

Last Updated

December 8, 2011

Record last verified: 2011-12

Locations